Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

4d ago, source: Zacks.com on MSN

The market expects Alpine Immune Sciences, Inc. (ALPN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known ...

Which Is a Better Investment, Alpine Immune Sciences Inc or Deciphera Pharmaceuticals Inc Stock?

5d ago, source: American Association of Individual Investors

Learn more about whether Alpine Immune Sciences Inc or Deciphera Pharmaceuticals Inc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Alpine Immune Sciences Inc

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Navigating 8 Analyst Ratings For Alpine Immune Sciences

27d ago, source: Business Insider

About Alpine Immune Sciences Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and ...

Alpine Immune Is Weighing Options After Takeover Interest

26d ago, source: Bloomberg L.P.

Alpine Immune Sciences Inc., a clinical-stage biotechnology company developing a treatment for inflammatory kidney diseases, is weighing options including a potential sale after attracting ...

Boston company to buy Alpine Immune Sciences for $4.9B

25d ago, source: The Business Journals

The Seattle biotech is developing a drug to treat kidney disease. Vertex Pharmaceuticals Inc. has agreed to buy Seattle-based biotech company Alpine Immune Sciences Inc. for $4.9 billion The ...

Vertex Pharma’s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

25d ago, source: MarketWatch

Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise by adding a potentially billion-dollar ...

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

26d ago, source: Stockhouse

targeted in 2H 2024 -- -- Company will host an investor call and webcast today at 5:15 pm ET -- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on ...

Alpine Immune Sciences Inc (34LA.SG)

18d ago, source: Yahoo Finance

SEATTLE, April 10, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory ...

Alpine Immune Sciences Inc.

25d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alpine Immune Sciences Inc.

26d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...